Brimonidine and latanoprost as adjunctive therapy

Ophthalmology

Volumn 110, Issue 1, 2003, Pages 6-8

  Camras, Carl B ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85058202718     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-6420(02)01553-1     Document Type: Letter

References (25)

1. S.T. Simmons M.L. Earl Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on β-blockers tolerance and peak intraocular pressure lowering. Alphagan/Xalatan Study Group Ophthalmology 109 2002 307 314 discussion 314–5
2. J.S. Schuman Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension Surv Ophthalmol 41 Suppl 1 1996 S27 37
3. J.S. Schuman B. Horwitz N.T. Choplin A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group Arch Ophthalmol 115 1997 847 852
4. R.P. LeBlanc Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2 Ophthalmology 105 1998 1960 1967
5. L.J. Katz Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily 1-year results in glaucoma patients. Brimonidine Study Group Am J Ophthalmol 127 1999 20 26
6. C.B. Camras C.B. Toris R.R. Tamesis Efficacy and adverse effects of medications used in the treatment of glaucoma Drugs Aging 15 1999 377 388
7. D.A. Lee J. Gornbein C. Abrams The effectiveness and safety of brimonidine as mono-, combination, or replacement therapy for patients with primary open-angle glaucoma or ocular hypertension a post hoc analysis of an open-label community trial. Glaucoma Trial Study Group J Ocul Pharmacol Ther 16 2000 3 18
8. S.T. Simmons T.W. Samuelson Comparison of brimonidine and latanoprost in the adjunctive treatment of glaucoma. Alphagan/Xalatan Study Group Clin Ther 22 2000 388 399
9. W.C. Stewart D.G. Day J.A. Stewart The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension Am J Ophthalmol 131 2001 631 635
10. T.R. Einarson N.A. Kulin D. Tingey M. Iskedjian Meta-analysis of the effect of latanoprost and brimonidine on intraocular pressure in the treatment of glaucoma Clin Ther 22 2000 1502 1515
11. W.C. Stewart D.G. Day J.A. Stewart Therapeutic success of latanoprost 0.005% compared to brimonidine 0.2% in patients with open-angle glaucoma or ocular hypertension J Ocul Pharmacol Ther 16 2000 557 564
12. W.C. Stewart E.D. Sharpe D.G. Day Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension J Ocul Pharmacol Ther 16 2000 251 259
13. A. Alm J. Stjernschantz Effects on intraocular pressure and side-effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group Ophthalmology 102 1995 1743 1752
14. C.B. Camras Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma a six-month, masked, multicenter trial in the United States. The United States Latanoprost Study Group Ophthalmology 103 1996 138 147
15. H.K. Mishima K. Masuda Y. Kitazawa A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study Arch Ophthalmol 114 1996 929 932
16. K. Hedman A. Alm A pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol Eur J Ophthalmol 10 2000 95 104
17. R.J. Derick A.L. Robin T.R. Walters Brimonidine tartrate a one-month dose response study [published erratum appears in Ophthalmology 1997;104:346] Ophthalmology 104 1997 131 136
18. C.B. Camras M.B. Wax R. Ritch Latanoprost treatment for glaucoma effects of treating for 1 year and of switching from timolol. United States Latanoprost Study Am J Ophthalmol 126 1998 390 399
19. H.K. Mishima Y. Kiuchi M. Takamatsu Circadian intraocular pressure management with latanoprost diurnal and nocturnal intraocular pressure reduction and increased uveoscleral outflow Surv Ophthalmol 41 Suppl 2 1997 S139 144
20. A.G.P. Konstas A.C. Maltezos S. Gandi Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma Am J Ophthalmol 128 1999 15 20
21. J.B. Martin D.L. Kasper In whose best interest? Breaching the academic-industrial wall [published erratum appears in N Engl J Med 2001;344:536] N Engl J Med 343 2000 1646 1649
22. T. Bodenheimer Uneasy alliance—clinical investigators and the pharmaceutical industry N Engl J Med 342 2000 1539 1544
23. A.S. Relman Separating continuing medical education from pharmaceutical marketing JAMA 285 2001 2009 2012
24. F. Davidoff C.D. DeAngelis J.M. Drazen Sponsorship, authorship, and accountability [editorial] N Engl J Med 345 2001 825 826 discussion 826–7
25. C.B. Camras D. Minckler Does that drug work? Pitfalls in studies on the efficacy and safety of glaucoma medications [editorial] Am J Ophthalmol 129 2000 87 89